NeoGenomics Reports Medicare Coverage For RaDaR Assay For Minimal Residual Disease And Recurrence In Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics has announced that Medicare will cover its RaDaR assay for minimal residual disease and recurrence in breast cancer. This is a significant development for the company as it expands the potential market for its product.
July 27, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics' RaDaR assay for breast cancer has received Medicare coverage, which could lead to increased sales and revenue for the company.
Medicare coverage for NeoGenomics' RaDaR assay means that the product is now accessible to a larger patient population, which could lead to increased sales and revenue for the company. This is a positive development for NeoGenomics and could potentially boost its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100